» Articles » PMID: 33398182

Broadly Effective Metabolic and Immune Recovery with C5 Inhibition in CHAPLE Disease

Abstract

Complement hyperactivation, angiopathic thrombosis and protein-losing enteropathy (CHAPLE disease) is a lethal disease caused by genetic loss of the complement regulatory protein CD55, leading to overactivation of complement and innate immunity together with immunodeficiency due to immunoglobulin wasting in the intestine. We report in vivo human data accumulated using the complement C5 inhibitor eculizumab for the medical treatment of patients with CHAPLE disease. We observed cessation of gastrointestinal pathology together with restoration of normal immunity and metabolism. We found that patients rapidly renormalized immunoglobulin concentrations and other serum proteins as revealed by aptamer profiling, re-established a healthy gut microbiome, discontinued immunoglobulin replacement and other treatments and exhibited catch-up growth. Thus, we show that blockade of C5 by eculizumab effectively re-establishes regulation of the innate immune complement system to substantially reduce the pathophysiological manifestations of CD55 deficiency in humans.

Citing Articles

SARS-CoV-2 enhances complement-mediated endothelial injury via the suppression of membrane complement regulatory proteins.

Wu J, Xu S, Li Z, Cong B, Yang Z, Yang Z Emerg Microbes Infect. 2025; 14(1):2467781.

PMID: 39945674 PMC: 11873982. DOI: 10.1080/22221751.2025.2467781.


The patient experience of CHAPLE disease: results from interviews conducted as part of a clinical trial for an ultra-rare condition.

Litcher-Kelly L, Ozen A, Ollis S, Feldman H, Yaworsky A, Medrano P Orphanet J Rare Dis. 2025; 20(1):68.

PMID: 39934837 PMC: 11817392. DOI: 10.1186/s13023-024-03436-y.


Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease).

Lin K, Mendell J, Davis J, Harnisch L J Pharmacokinet Pharmacodyn. 2024; 51(6):905-917.

PMID: 39349796 PMC: 11579122. DOI: 10.1007/s10928-024-09941-8.


Cellular and molecular basis of proximal small intestine disorders.

Bildstein T, Charbit-Henrion F, Azabdaftari A, Cerf-Bensussan N, Uhlig H Nat Rev Gastroenterol Hepatol. 2024; 21(10):687-709.

PMID: 39117867 DOI: 10.1038/s41575-024-00962-9.


Impact of High-Temperature Feeds on Gut Microbiota and MAFLD.

Xue L, Li K, Jia Y, Yao D, Guo X, Zhang S J Microbiol Biotechnol. 2024; 34(9):1789-1802.

PMID: 39113196 PMC: 11473614. DOI: 10.4014/jmb.2405.05023.


References
1.
Waldmann T, Steinfeld J, DUTCHER T, DAVIDSON J, GORDON Jr R . The role of the gastrointestinal system in "idiopathic hypoproteinemia". Gastroenterology. 1961; 41:197-207. View

2.
Ozen A, Comrie W, Ardy R, Conde C, Dalgic B, Beser O . CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. N Engl J Med. 2017; 377(1):52-61. PMC: 6690356. DOI: 10.1056/NEJMoa1615887. View

3.
Kurolap A, Eshach-Adiv O, Hershkovitz T, Paperna T, Mory A, Oz-Levi D . Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy. N Engl J Med. 2017; 377(1):87-89. DOI: 10.1056/NEJMc1707173. View

4.
Ozen A . CHAPLE syndrome uncovers the primary role of complement in a familial form of Waldmann's disease. Immunol Rev. 2018; 287(1):20-32. DOI: 10.1111/imr.12715. View

5.
Mevorach D . Clearance of dying cells and systemic lupus erythematosus: the role of C1q and the complement system. Apoptosis. 2010; 15(9):1114-23. DOI: 10.1007/s10495-010-0530-8. View